With the coming launch of new products for various technologies, which companies will lead the nanopore sequencing IP landscape?
Key features of the report
- IP trends, including time-evolution of published patents, and countries of patent filings
- Patents’ current legal status
- Ranking of main patent assignees
- Key players’ IP position and relative strength of their patent portfolios
- IP analysis of nanopore technologies (solid-state nanopores, protein nanopores, and hybrid nanopores) and IP analysis of applications (oncology, plant genetics, infectiology, etc.)
- Main patent litigations
- Description of key players and key patents
- Excel database with all patents analyzed in this report, including technology segmentation
Table of contents
Main assignees mentioned 24
Executive summary 31
Patent landscape overview 36
- Time evolution of patent publications
- Countries of patent filings
- Time evolution, by country of filing
- Ranking of most prolific patent applicants
- Mapping of main current IP holders
- Mapping of main current IP applicants
Main patent assignees analysis 43
- Strength index of patent portfolios
- Patent citation analysis
- IP blocking potential of patent applicants
- Time evolution for main patent applicants
- Countries of filing for main patent applicants
- Summary of applicant’s portfolios
- Patent applicants IP network
- IP leadership of patent applicants
- Granted patents nearing expiration
- Degree of specialization
- Potential future plaintiffs
Analysis, by technology 66
- Technical segmentation, by technology
- Main assignees, by technology
- Time evolution, by technology
- Time evolution, by country
- Legal status, by technology
Analysis, by application 82
- Technical segmentation, by application
- Main assignees, by application
- Time evolution, by application
- Legal status, by application
Main patent ligitations 96
- Illumina vs. Oxford Nanopore Technologies
- Pacific Biosciences vs. Oxford Nanopore Technologies
- University of California vs. Roger Chen and Genia Technologies
IP profile for key players 101
- Harvard University
- University of California
- Chinese University of Hong Kong
- Oxford Nanopore Technologies
- Two Pore Guys
- Pacific Biosciences of California
- Agilent Technologies
- Thermo Fisher Scientific
For each selected player:
- Company profile and news
- Summary of their patent portfolio
- Key patent families
Other key patents 163
KnowMade Company presentation 180
NANOPORE SEQUENCING IS A PROMISING TECHNOLOGY IN THE FIELD OF NEXT-GENERATION SEQUENCING
Nanopore sequencing is one of the next-generation sequencing (NGS) technologies believed to be capable of revolutionizing DNA analysis. Different modalities of nanopore sequencing have been developed over time, including protein nanopores, solid-state nanopores, and hybrid nanopores. The technology enables production of ultra-long reads at very high speeds, reducing sample preparation time as well as the data-processing time required to reassemble the reads into their original sequence.
This novel technology could tap into a brand-new sector of customers who may require genetic fingerprinting for fast identification of cancer types and pathogens. According to DataBridge, the global NGS market will grow fast, from $US 4.83B in 2017 to $US 16.35B in 2024, at an estimated compound annual growth rate (CAGR) of 19.2% (from 2018 – 2024).
Today, Oxford Nanopore Technologies is the only company to have brought nanopore-based sequencers to market. However, several other companies are developing their own technology, and Oxford Nanopore may not be the only supplier of nanopore-based sequencers much longer. For example, Two Pore Guys has announced the release of its product suite in spring 2019.
With new products launching in the near future, it is crucial to understand the intellectual property (IP) position and strategy of established nanopore sequencing players, while identifying the IP newcomers and the threat they represent. To this end, Knowmade has identified the key IP players involved in nanopore-based sequencing technologies (protein, solid-state, and hybrid) and their applications (oncology, plant genetics, etc.). Such knowledge can help detect business risks and opportunities, anticipate emerging applications, and enable strategic decisions to strengthen one’s market position.
The analysis of the time-evolution of patent publications shows an important increase in nanopore sequencing-related patenting activity from 2008 – 2013. This increase follows the work of academic research teams (Harvard University and University of California) that proved the concept of nanopore sequencing.
Even though the industrial players developing nanopore-based sequencing are steadily gaining importance, Harvard’s patent portfolio remains the strongest, followed by Illumina, Agilent, University of California, and Roche, whose influence in the IP landscape is growing. In fact, Roche is now the most prolific applicant in nanopore sequencing. Contrarily, Oxford Nanopore Technologies’ patent portfolio is not the strongest, but the company benefits from the numerous partnerships it has with universities (Harvard, University of California, and Boston University). Moreover, several companies with strong experience in microelectronics and semiconductors (Hitachi, IBM, Samsung Electronics, Intel, and GlobalFoundries) have recently filed patents claiming solid-state nanopores.
Most main patent assignees have developed an international IP strategy. American players have a strong presence in the US and Europe. Some European companies are also well ranked, and a few Asian firms play a significant role in the patent protection of nanopore sequencing.
ANALYZING PATENTS FOR EACH MAIN NANOPORE TECHNOLOGY AND APPLICATION
Patents are categorized by nanopore technology (protein, solid-state, and hybrid) and by main application. Also, IP trends and the relative strength of each main patent assignee was analyzed. These findings reveal that solid-state nanopore-related patents are more numerous than those related to protein nanopore or hybrid nanopore. From an IP perspective, Roche leads for technologies related to protein nanopore, and Oxford Nanopore Technologies leads the solid-state nanopore and hybrid nanopore segments. Regarding applications, the main patented application for nanopore sequencing is oncology. Plant genetics, epigenetics, and transcriptomics are also important application domains for nanopore sequencing. Among the main applications for nanopore sequencing, microbiome analysis is the most recent, but already a few companies are positioned in this segment.
IP PROFILE OF MAIN PLAYERS, AND ANALYSIS OF THEIR KEY PATENTS
KnowMade’s study includes IP profiles for key players and a description of their key patents. The key-patent analysis includes the legal state of the family for each of the main territories, the number of received citations, the review of main claims, the description of interesting features disclosed about the innovation, and relevant figures illustrating how the innovation works. This section also covers patents involved in litigations.
This report also includes an Excel database containing the >7,200 patents analyzed in this study. This useful database allows for multi-criteria searches and includes patent publication numbers, hyperlinks to original documents, priority date, title, abstract, patent assignees, and each patent’s current legal status, as well as nanopore technologies and applications.
Related Reports & Monitors
Status of the Microfluidics Industry 2019
Market & Technology
Artificial Intelligence in Medical Diagnostics – Patent landscape analysis
Need to discuss?
We are open for discussionContact us